Lung Cancer in COPD Patients: Development and Validation of the COPD Lung Cancer Screening Score (COPD-LUCSS)
de-Torres JP [ES] (1), Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J [ES], Campo A [ES], Alcaide AB [ES], García-Granero M, Celli BR, Zulueta JJ.
(1) Clinica Universidad de Navarra, Pulmonary, Pamplona, Spain
Revisão:American Journal of Respiratory and Critical Care Medicine
Patients with chronic obstructive pulmonary disease (COPD) are at high-risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs.
Develop a predictive score for LC risk for patients with COPD.
The Pamplona-IELCAP LC screening study (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD lung cancer screening score (COPD-LUCSS) to be validated in P-IELCAP.
By regression analysis, age>60, BMI<25 kg/m2, pack-years history>60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS that ranges from 0 to 10 points.
Two COPD-LUCSS risk categories were proposed: low risk (scores 0-6) and high risk (scores 7-10). In comparison to low risk patients, in both cohorts LC risk increased 3.5 fold in the high-risk category.
The COPD-LUCSS is a good predictor of lung cancer risk in COPD patients participating in LC screening programs. Validation in two different populations adds strengths to the findings.
CITAÇÃO DO ARTIGO Am J Respir Crit Care Med. 2014 Dec 18
A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.
Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.
Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.